And what happened after that Friday? As the Street continued to assess the trial results, the stock price continued down for seven consecutive days following the announcement to reach a low close of $7.66 on April 12th--a period during which the biotech indices were in an uptrend.
I can't believe you are trying to sell the PDD OLE results as a win when the data clearly showed a sell on the news event. That being said, the results did show a positive signal. It's just that the Street wasn't impressed whatsoever. You can attribute a lot of that to the low patient count.